Background {#Sec1}
==========

Carbapenem antibiotics (including imipenem, meropenem, ertapenem and doripenem), with a broad spectrum of antibacterial activity, play an extremely important role in the field of anti-infective treatment for severe infections. They are stable against most chromosomal broad-spectrum beta-lactamases and cephalosporinases found in Gram-negative bacteria \[[@CR1], [@CR2]\]. However, with the wide application of carbapenem antibiotics, carbapenem-hydrolyzing beta-lactamases, also named carbapenemases, have been increasingly found in Gram-negative pathogens. These beta-lactamases may limit the use of carbapenem antibiotics and cause treatment failure in severe infections \[[@CR3], [@CR4]\]. Carbapenemases, accompanied with drug resistance, constantly threat global health \[[@CR5]\].

Carbapenemases belong to Ambler class A, B or D beta-lactamases and are mostly produced by Enterobacteriaceae, *Pseudomonas aeruginosa* or *Acinetobacter baumannii* \[[@CR6], [@CR7]\]. Class A carbapenemases can effectively hydrolyze carbapenem antibiotics by binding on active-site serine. These carbapenemases include the members of SME (*Serratia marcescens* enzyme), NMC (non-metallo enzyme carbapenemase), IMI (imipenem-hydrolyzing), GES (Guiana extended spectrum) and the most important KPC (*Klebsiella pneumoniae* carbapenemase) beta-lactamases \[[@CR8]\]. Class B carbapenemases are also called Metallo-beta-lactamases (MBLs). These zinc-dependent enzymes can hydrolyze beta-lactams and are not inhibited by beta-lactamase inhibitors. Class B carbapenemases include IMP (imipenemase), VIM (Verona integron-encoded MBL), SPM (Sao Paulo MBL), GIM (German imipenemase) and NDM (New Delhi MBL) groups \[[@CR9], [@CR10]\]. They are mainly detected in *P. aeruginosa* and Enterobacteriaceae \[[@CR11]\]. Class D carbapenemases are primarily detected in *A. baumannii* and Enterobacteriaceae (especially *K. pneumoniae*). They consist of oxacillinases (OXAs) which prefer to hydrolyze oxacillin or cloxacillin at higher rates than penicillin. Most members of OXAs are not susceptible to beta-lactamase inhibitors, but may be inhibited by NaCl \[[@CR12], [@CR13]\].

For carbapenem-resistant Gram-negative bacteria, there are limited antimicrobial treatment options \[[@CR14], [@CR15]\]. Novel beta-lactam/beta-lactamase inhibitors (such as ceftazidime/avibactam) may be available treatment options, while poor use and rapid emergence of resistance restrict their application \[[@CR16], [@CR17]\]. With less effective monotherapy and increasing resistance, evidence of retrospective studies on combination therapy of Gram-negative bacterial infections is increasing \[[@CR18]--[@CR20]\]. Many combination therapies have shown better survival and mortality reduction compared with monotherapy regimens, especially patients with a high predicted mortality \[[@CR21]--[@CR23]\]. The carbapenem-based combination regimens exert good synergistic results and low resistance \[[@CR24], [@CR25]\]. In these combination regimens, double-carbapenem therapy (DCT) is first attempted in three Greek patients in 2013 \[[@CR26]\]. This study demonstrated bactericidal effect and clinical success of DCT and attributed to inactivating carbapenemases made by one carbapenem, mainly ertapenem. Since then, more and more clinical studies about DCT have been reported, while its effectiveness and safety have not been comprehensively addressed. In the present systematic review and meta-analysis, we aimed to evaluate efficacy and safety of DCT and other antibiotic regimens in patients with multidrug resistant (MDR) Gram-negative bacterial infections.

Methods {#Sec2}
=======

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines \[[@CR27]\] and was registered to PROSPERO (No. CRD42019129979) \[[@CR28]\].

Search method and data extraction {#Sec3}
---------------------------------

Literature search was performed in English databases, including Cochrane Library, PubMed, Embase and Web of Science, and Chinese databases, including SinoMed, CNKI and WANFANG MED DATA, from database establishment to February 3rd, 2019. No restrictions on language and geographic region were applied. Screening of abstract and full text was independently performed by two authors (YYL and JW). Search terms were set as "Double carbapenem", "Dual carbapenem", "Carbapenem" AND "Double", "Carbapenem" AND "Dual", "Carbapenem" AND "Joint", "Carbapenem" AND "Combination". Reference lists of included articles and relevant reviews were also searched.

In order to ensure accuracy, data extraction was independently carried out by two authors (YYL and JW). Controversial issues were resolved by consensus. When necessary, the corresponding authors were requested to provide unpublished data via e-mail. The following information was extracted: first author name, publication year, region, study design, characteristics of patients (sample size, sex and age), type of infection, type of organism, administered antibiotics, antimicrobial susceptibility test, treatment duration, follow-up time and outcomes.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Randomized controlled trials (RCTs), cohort and case-control studies as well as case series and case reports were included. Studies focusing on patients with MDR Gram-negative bacterial infections were considered eligible for the meta-analysis, if such studies had reported available data of clinical response, microbiological response, adverse events, or mortality for the treatment of DCT. Studies which contained DCT in both treatment and control groups were excluded. Studies on experimental animal models and in vitro studies were excluded.

Quality assessment {#Sec5}
------------------

Regarding risk of bias, the quality of each selected RCT was independently assessed by the two authors with the Cochrane Collaboration's tool \[[@CR29]\]. The non-randomized studies were assessed with the Newcastle-Ottawa Scale (NOS) \[[@CR30]\]. The risk of bias was evaluated as low, median or high by assigning or scoring each item separately. Any differences were resolved through consensus.

Definitions and outcomes {#Sec6}
------------------------

The definitions of infections in the current meta-analysis were based on the definitions provided by the individual studies. The outcomes mainly focused on the efficacy and safety of DCT, including clinical response, microbiological response, adverse events and mortality. Clinical response was defined as resolution of clinical signs and symptoms of the infections by therapy completion. Microbiological response was defined as the absence of pathogens from subsequent specimen cultures.

Statistical analysis {#Sec7}
--------------------

Meta-analysis was performed by Review Manager 5.3. Odds ratios (ORs) were calculated as effect measures, and *P* \< 0.05 was considered as statistically significant. The fixed effects model was used to obtain pooled estimates of ORs, including 95% confidence interval (CI) \[[@CR31]\]. Statistical heterogeneity was tested by □^2^ test (*P* ≤ 0.10 to indicate statistically significant) and quantified using I^2^ statistics \[[@CR32]\]. Subgroup and sensitivity analyses were performed according to treatment regimens in control groups. The publication bias was assessed through visual inspection of funnel plot.

Results {#Sec8}
=======

Study identification {#Sec9}
--------------------

A total of seven databases and 1972 unique references were initially identified. Overall, 28 studies were selected for full-text review, and 21 studies met our inclusion criteria. For these 21 studies, three trials \[[@CR33]--[@CR35]\] were cohort or case-control studies, and 18 reports \[[@CR26], [@CR36]--[@CR52]\] were case series or case reports. The flow diagram (Fig. [1](#Fig1){ref-type="fig"}) showed the detailed screening and selection process for the trials included in our analysis. Table [1](#Tab1){ref-type="table"} summarized the basic characteristics of cohort or case-control studies included, and such information for case series or case reports was performed in Table [2](#Tab2){ref-type="table"}. Our study covered patients with MDR Gram-negative bacterial infections, and DCT was used to compare with other available antibiotics. Fig. 1Flowchart of study selection. Abbreviations: DCT: double-carbapenem therapyTable 1Basic characteristics of cohort/case-control studies includedAuthor/YearRegionDesignInfectionOrganismSample size (D/C)Age^a^\
(years)\
(D/C)AntibioticsAntimicrobial susceptibility test (μg/ml) (D/C)Treatment duration^a^ (days) (D/C)Follow-up time (days) (D/C)Outcomes^b^DCTControlPascale, 2017 \[[@CR33]\]Italyretrospective studyVAP (51), HAP (23), BSI (16), SBSI (49), CVCI (18), UTI (12), IAI (19), SSTI (12), MSI (7)CRKP48/96D: 55.5 ± 15C: 61.3 ± 12ETP 1 g q12h/2 g q24hMEM 2 g q8h(3 h infusions)CSTGENTGCmonotherapy or combinedCAB ≥1 R 48/96CST ≤2 S 28/64GEN ≤2 S 15/72TGC ≤1 S 16/58D: 17 (11.5--25.5)C: 11.5 (7.5--15.5)90/90①②③Venugopalan, 2017 \[[@CR34]\]USAretrospective studyBSICRKP18/18D: 72(61--83)C: 62(48--75)ETP 1 g q24hDOR 2 g q8h(4 h infusions)DOR + CSTETP -DOR^c^ 8 (8--32)/−CST^c^ 8 (0.5--12)/1.25 (0.75--3.5)D: 12 (7--14)C: 9 (7--12)30/30①②③Cancelli, 2018 \[[@CR35]\]Italyretrospective studyPNA (12), BSI (14),UTI (37), STI (12)CPCRE21/34D: 62.28 ± 12.1C: 61.18 ± 17ETP 1 g/dMEM 6 g/dCSTCST + TGC/GEN/RIF/CABAMGAMG + CABMEM + FLQETP^d^ 256 R 20/− ^e^MEM^d^ 256 R 20/− ^e^CST R 10/6TGC R 11/18RIF -AMG R 8/4FLQ R 21/31D: 39.2 ± 29.5C: 20.4 ± 14.160/60①③Abbreviations: *D* double-carbapenem therapy (DCT) group, *C* the control group, *PNA* pneumonia, *HAP* hospital-acquired pneumonia, *VAP* ventilator-associated pneumonia, *BSI* bloodstream infection, *SBSI* secondary bloodstream infection, *CVCI* central venous catheter infection, *UTI* urinary tract infection, *IAI* intra-abdominal infection, *SSTI* skin and soft tissue infection, *STI* soft tissue infection, *MSI* multiple site infection, *CRKP* carbapenem-resistant *K. pneumoniae*, *CPCRE* carbapenemase producing carbapenem-resistant Enterobacteriaceae, *MEM* meropenem, *ETP* ertapenem, *DOR* doripenem, *GEN* gentamicin, *CST* colistin, *TGC* tigecycline, *RIF* rifampicin, *AMG* aminoglycosides, *CAB* carbapenem antibiotics, *FLQ* fluoroquinolones, *S* sensitive, *R* resistant-: not reported^a^. Data are expressed as mean ± standard deviation (SD), or median (range or interquartile range)^b^. ①clinical response; ②microbiological response; ③mortality^c^. The minimal inhibitory concentration (MIC) of antibiotics is expressed as mean or median (interquartile range)^d^. The MIC of antibiotics is represented by MIC50^e^. The remaining strains are not availableTable 2Basic characteristics of case series/case reports includedAuthor/\
YearRegionDesignSample sizeSexAge^a^\
(years)InfectionOrganismDCTCombined antibioticsAntimicrobial susceptibility test (μg/ml)Treatment duration^a^\
(days)Follow-up time^a^\
(days)OutcomesCeccarelli, 2013 \[[@CR51]\]Italycase report1male65SBSI, VAPcombinedMDR, KPC-III-producing KPETP 0.5/1 g q24hDOR 0.25/0.5/1 g q8h(4 h infusions)--ETP ≥8 RDOR R2830clinical responsemicrobiological responseGiamarellou, 2013 \[[@CR26]\]Greececase report3male (1)female (2)544244SBSI (2), UTI (3)PDR, KPC-II-producing KPETP 1 g q24hMEM 1/2 g q8h (2)DOR 2 g q8h (1)--ETP \> 8 RMEM \> 16 RDOR \> 8 R20141030021180clinical response 3/3microbiological response 3/3Oliva, 2014 \[[@CR38]\]Italycase report3male (3)--API (1), BSI (2)PDR, CPKPETP 0.5/1 g q24hMEM 1 g q12h/2 g q8h--ETP 128 R (1), 256 R (2)MEM 128 R (1), 256 R (2)21224--clinical response 3/3microbiological response 3/3demised 1/3Camargo, 2015 \[[@CR52]\]USAcase report1female64IAI, VAP, BSIcombinedXDR, KPC-producing KPETP 1 g q24hMEM 1 g q12hCSTETP -MEM -CST 12 R12--microbiological failureemergence of colistin resistanceswitched to AVC + ETPChua, 2015 \[[@CR41]\]Singaporecase report2male (2)6277SSI (1), HAP (1)KPC-producing KPETP 0.5/1 g q24hDOR 0.5/1 g q8h(4 h infusions)PMB + CSTPMBETP 4 (1), \> 32 (1)DOR 8 (1), − (1)PMB 1 (1), − (1)CST -1210 + 73013clinical response 2/2microbiological response 2/2demised 2/2Oliva, 2015 \[[@CR37]\]Italycase report1female75CVCIPDR, KPC-producing KPETP 1 g q24hMEM 2 g q8hCSTETP 128 RMEM 256 RCST 32 R21--clinical responsemicrobiological responseTumbarello, 2015 \[[@CR50]\]Italycase report8--≥18BSIKPC-producing KPETPMEM--ETP -MEM -≥214demised 3/8Alessandra, 2016 \[[@CR46]\]Italycase series15male (10)female (5)60.9 ± 10.9UTI (8), SSTI (2), EPI (2), PNA (1), MSI (2)KPC-producing KPETP 1 g (1 h infusions)MEM 2 g q8h (3 h infusions)--ETP \> 8 R (14)MEM \> 16 R (14)ETP, MEM \> 32 R (1)15 (7--150)60clinical response 12/15microbiological response 12/15adverse events 3/15(nausea, hypernatremia and seizures)demised 1/15Cprek, 2016 \[[@CR47]\]USAcase series18male (10)female (8)62.5(51--67)BSI (7), PNA (5), IAI(2), UTI (3), SSSI (1)CRKPETP 1 g q24hMEM 2 g q8h (17)DOR 0.5 g q8h (1)DOX, GENAMK, CIPTGC + PMBCIP + TGCGEN + DOXCAB \> 1 RDOX, GEN, AMK, CIP, TGC, PMB -17 (2--72)30clinical response 7/18microbiological response 11/14adverse events 2/18(2 seizures)demised 5/18Montelione, 2016 \[[@CR40]\]Italycase report1male62APIXDR, CPKPETP 1 g q24hMEM 2 g q8h--ETP 128 RMEM 256 R281095clinical responsemicrobiological responseOliva, 2016 \[[@CR39]\]Italycase report1female61SSI, HAP, SBSIcombinedKPC-producing ECETP 0.5 g q24h (1 h infusions)MEM 2 g q12h (3 h infusions)--ETP 16 RMEM 32 R10--clinical responsemicrobiological responsedemisedBasaranoglu,2017 \[[@CR44]\]Turkeycase report3male (2)female (1)3 months8 months3SBSI (1), CRBSI (2)MDR KPETP 0.015 g/kg q12hMEM 0.02--0.04 g/kg q8hCIP + TGCAMK + TGC + CIPCIP + AMK + CSTETP \> 8 R (1), \> 32 R (2)MEM \> 6 R (1), \> 32 R (2)CIP \> 2 R (1), \> 4 R (2)TGC 1 S (1), 2 S (1), \> 2 R (1)AMK 16 IR (1), \> 64 R (2)CST -141526--clinical response 2/3microbiological response 3/3Nekidy, 2017 \[[@CR36]\]United Arab Emiratescase report1female62SSI, UTI, PNA, BSI combinedMDR KPETP 1 g q24hMEM 1 g q8h--ETP ≥8 RMEM -28 + 7, 10, 14, 28, 14--clinical responsemicrobiological responseSouli, 2017 \[[@CR45]\]Greececase series27male (15)female (12)59(15--83)BSI (13), UTI (12), VAP (1), EVDI (1)PDR/XDR, KPC-II-producing KPETP 1 g q24h (1 h infusions)MEM 2 g q8h (3 h infusions)--ETP \> 8 IRMEM ≥2 IR10 (5--28)28 (9--200)clinical response 21/27microbiological response 20/27adverse events 4/27(generalized rash, eosinophilia and 2 aseptic meningitis)demised 8/27Carrasco,2018 \[[@CR42]\]Spaincase report1female36BSIXDR, KPC-producing KPETP 1 g q24hMEM 2 g q8h (3 h infusions)--ETP ≥32 RMEM ≥32 R1490clinical responsemicrobiological responseGalvão, 2018 \[[@CR43]\]Brazilcase report1male59SSI, SBSIcombinedXDR, KPC-producing KPETP 1 g q24hMEM 2 g q8h (4 h infusions)AMK + LZD+FCAETP ≥8 RMEM ≥16 RAMK 4 SLZD -FCA -45--multiple organ failure and demisedLiang, 2018 \[[@CR48]\]Chinacase report1male50SBSIXDR KPETP 1 g q24h (1 h infusions)MEM 1 g q8h (3 h infusions)--ETP RMEM R9--clinical responsemicrobiological responseRosa, 2018 \[[@CR49]\]USAcase report2male (1)female (1)5735UTINDM-harboring KP/ECETP 1 g q24hMEM 1 g q12h (4 h infusions)FOFETP -MEM ≥16 RFOF 12 S (1), 256 R (1)14--clinical response 2/2microbiological response 2/2Abbreviations: *DCT* double-carbapenem therapy, *PNA* pneumonia, *HAP* hospital-acquired pneumonia, *VAP* ventilator-associated pneumonia, *BSI* bloodstream infection, *SBSI* secondary bloodstream infection, *EPI* endovascular prosthesis infection, *API* Aortic periprosthetic infection, *CVCI* central venous catheter infection, *CRBSI* catheter-related bloodstream infection, *UTI* urinary tract infection, *IAI* intra-abdominal infection, *SSTI* skin and soft tissue infection, *SSSI* skin and skin structure infection, *SSI* surgical site infection, *EVDI* external ventricular drainage infection, *MSI* multiple site infection, *KP Klebsiella pneumoniae*, *EC Escherichia coli*, *CRKP* carbapenem-resistant *K. pneumoniae*, *CPKP* carbapenemase-producing *K. pneumoniae*, *KPC K. pneumoniae* carbapenemase, *KPC-II* a type II carbapenem against KPC-producers, *KPC-III* a type III carbapenem against KPC-producers, *NDM* New Delhi Metallo-beta-lactamase, *MDR* multidrug resistant, *XDR* extensively drug resistant, *PDR* pandrug resistant, *MEM* meropenem, *ETP* ertapenem, *DOR* doripenem, *CAB* carbapenem antibiotics, *CST* colistin, *GEN* gentamicin, *TGC* tigecycline, *CIP* ciprofloxacin, *AMK* amikacin, *FOF* fosfomycin, *LZD* linezolid, *PMB* polymyxin B, *DOX* doxycycline, *FCA* fluconazole, *AVC* ceftazidime/avibactam, *S* sensitive, *I* intermediate, *R* resistant-: not reported^a^. Data are expressed as mean ± standard deviation (SD), or median (range or interquartile range)

The three cohort or case-control studies were composed of 235 patients with carbapenem-resistant Enterobacteriaceae (CRE) infection. Colistin, tigecycline and aminoglycoside (especially gentamicin) monotherapies or combined regimens were compared with DCT in all patients. DCT regimens included ertapenem+meropenem and ertapenem+doripenem. Ertapenem was used at a daily dose of 1--2 g. Meropenem and doripenem were administered every 8 h at a high dose (2 g), mainly adopting the extended infusion. Dose was adjusted according to creatinine clearance if renal function was abnormal.

Study quality {#Sec10}
-------------

The NOS assessment tool included three subjects as follows: the selection of study groups, the comparability between the groups and the ascertainment of exposure or outcome. Studies with a score of 7--9 were considered as high-quality studies \[[@CR53], [@CR54]\]. Table [3](#Tab3){ref-type="table"} summarized the risk of bias. All studies in our meta-analysis had high qualities (7 score) and low risk for sequence generation and allocation concealment. Table 3Risk of bias assessed by NOS assessment toolAuthor/YearDesignSelectionComparabilityOutcome\
/ExposureNOS\
scorePascale, 2017case-control study⁕⁕⁕⁕⁕⁕⁕7Venugopalan, 2017cohort study⁕⁕⁕⁕⁕⁕⁕7Cancelli, 2018cohort study⁕⁕⁕⁕⁕⁕⁕7

Clinical response {#Sec11}
-----------------

The data pooling from three studies consisting of 235 patients reported no significant difference between DCT-treated patients and those treated with other antibiotics (OR = 1.74, 95% CI = 0.99--3.06, *P* = 0.05) (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Forest plot of clinical response for patients with CRE infection. Abbreviations: CRE: carbapenem-resistant Enterobacteriaceae; CI: confidence interval

Microbiological response {#Sec12}
------------------------

Two studies consisting of 158 patients had reported the microbiological response. No significant difference was detected in patients with CRE infection between DCT and control groups (OR = 1.90, 95% CI = 0.95--3.80, *P =* 0.07) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plot of microbiological response for patients with CRE infection

Adverse events {#Sec13}
--------------

No studies had recorded adverse events.

Mortality {#Sec14}
---------

Three studies consisting of 233 patients had reported the mortality with 30 \~ 60 days of follow-up visit. Compared with the control groups, DCT showed a lower mortality in patients with CRE infection (OR = 0.44, 95% CI = 0.24--0.82, *P =* 0.009) (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Forest plot of mortality for patients with CRE infection

Summary of case series or case reports {#Sec15}
--------------------------------------

A total of 18 case series or case reports composed of 90 patients were assessed. DCT regimens mainly consisted of ertapenem+meropenem and ertapenem+doripenem. Infection types included pneumonia, bloodstream infection, urinary tract infection, intra-abdominal infection, skin infection, surgical site infection and so on. The number of patients with bloodstream infection was the highest (31 patients, 34.4%). Followed by urinary tract infection (26 patients, 28.9%). The infections were primarily caused by MDR *K. pneumoniae*. Among 90 patients, clinical response was reported in 59 (65.6%) patients, while microbiological response was found in 63 (70%) patients. In patients with bloodstream infection, clinical and microbiological responses were 16/31 (51.6%) and 20/31 (64.5%), respectively. While both clinical and microbiological responses were 21/26 (80.8%) in patients with urinary tract infection. Nine cases of adverse events were reported, including seizures (three cases), aseptic meningitis (two cases), generalized rash (one case), eosinophilia (one case), nausea (one case) and hypernatremia (one case). The number of patients demised was 22 (24.4%), and 10 cases of them were reported to decease in spite of clinical or microbiological improvement.

Discussion {#Sec16}
==========

In 2011, Bulik and Nicolau \[[@CR55]\] first proposed the idea of DCT against KPC-producing *K. pneumoniae* by in vitro and mouse thigh infection model experiments. In 2013, Giamarellou et al. \[[@CR26]\] reported that DCT successfully cured three patients with bloodstream infection and urinary tract infection caused by KPC-producing *K. pneumoniae*. Since then, DCT had been increasingly reported in clinical studies, no matter case series or case reports, cohort or case-control studies. Unfortunately, there were no RCTs available so far. To the best of our knowledge, our research was the first systematic review and meta-analysis of DCT to date, though two reviews had reported parts of DCT-treated patients with CRE infection. Our study contained three cohort or case-control studies consisting of 235 patients with CRE infection and 18 case series or case reports consisting of 90 patients. Most patients suffered from critical infections. The infection types mainly included pneumonia, bloodstream infection and urinary tract infection. Generally, the patients tolerated DCT regimens well. Only three case series had reported nine cases of adverse events, mainly including seizures and meningitis. Moreover, none of the adverse events led to interruption of treatment. Our meta-analysis demonstrated that though no obvious advantages in clinical and microbiological responses were noticed, the mortality in DCT regimens was lower compared with the control groups for CRE infection. In case series or case reports, ertapenem-containing regimens were the main pattern of DCT, which were applied to complicated severe infections caused by MDR Gram-negative bacteria. Our result was consistent with previous published reviews of DCT for the treatment of carbapenemase-producing *K. pneumoniae* caused critical infections \[[@CR56]\] or CRE caused bloodstream infection \[[@CR57]\] which both suggested that DCT regimens might be an effective and safe strategy to treat carbapenemase-producing *K. pneumoniae* or CRE. Moreover, White et al. \[[@CR57]\] also revealed DCT exhibited lower mortality in the treatment of CRE bloodstream infection compared with polymyxin-based regimens. Oliva A et al. \[[@CR58]\] compared DCT + colistin with DCT for the treatment of 32 patients with multiple infections caused by carbapenem-resistant *K. pneumoniae*. The result did not support that DCT + colistin was superior to DCT alone with similar clinical response and mortality in both groups.

DCT regimens have been proven to be effective in many in vitro and animal studies. In vitro studies \[[@CR59], [@CR60]\] have confirmed the synergistic effects of DCT regimens against carbapenemase-producing *K. pneumoniae*. Another in vitro study \[[@CR61]\] has evaluated the synergistic activity of 10 double or triple combination regimens based on meropenem against carbapenemase-producing *K. pneumoniae*. The results show that the combination of meropenem and ertapenem is the most effective strategy in double combination regimens. DCT against MDR Gram-negative bacterial infections has also been supported by animal model data. The combination of ertapenem and doripenem has been observed to statistically decrease the bacterial density compared with doripenem monotherapy in a mouse thigh model infected with carbapenem-resistant *K. pneumoniae* \[[@CR55]\]. The combination of doripenem and ertapenem has also exhibited a greater efficacy than doripenem alone at 72 h for KPC-producing *K. pneumoniae* infection in a neutropenic murine model with thigh infection \[[@CR62]\].

The synergistic effects of DCT regimens mainly focus on the mechanism in combination with ertapenem. Ertapenem is considered to be the most sensitive to KPC enzyme in carbapenem antibiotics \[[@CR63]\]. It can be hypothesized that ertapenem has preferential affinity with KPC and can consume the carbapenemases \[[@CR55]\]. When ertapenem is combined with another carbapenem antibiotic, KPC is decreased per unit time so that another carbapenem antibiotic is hydrolyzed less. Higher concentration of another carbapenem antibiotic kills KPC-producing *K. pneumoniae* better \[[@CR26]\]. An alternative explanation is that during treatment, ertapenem decreases the initial inoculum density by acting as a suicide substrate, thereby permitting doripenem to express its successful activity against an already reduced and manageable inoculum \[[@CR64]\]. However, an in vitro study \[[@CR59]\] has indicated that in DCT, the imipenem-containing combinations show the most efficacy in the treatment for carbapenemase-producing *K. pneumoniae* infection, while ertapenem may not be the best option to inactivate carbapenemases. This may be related to particularly enhanced in vitro activity of imipenem-containing combinations, even imipenem at sub-inhibitory concentrations \[[@CR65]\]. However, in vivo data on imipenem-containing DCT are limited, which may be attributed to the central nervous system toxicity of imipenem and short stability of intravenous preparation \[[@CR56], [@CR66]\]. Meanwhile, meropenem can synergistically exert antibacterial effects by binding to the bacterial target, especially if minimal inhibitory concentration (MIC) value of meropenem is ≤128 μg/ml \[[@CR60]\]. Further investigation is required since the treatment mechanism of DCT has not been extensively explored.

Although all available clinical evidence was included, there were four limitations in our systematic review and meta-analysis. Firstly, the studies included in the meta-analysis were all cohort or case-control studies, with case series or case reports as a supplement. The three studies including patients with CRE infection were all retrospective. The grade of evidence was insufficient. Secondly, publication and selective bias might exist. Two of three studies were from Italy, increasing the risk of bias due to geographic reasons. Thirdly, all the included studies did not provide information of resistance changes of pathogens after DCT exposure. Therefore, we were unable to know if excessive carbapenem exposure would lead to greater carbapenem resistance. At last, none of the antibiotics in control groups involved novel beta-lactam/beta-lactamase inhibitors (such as ceftazidime/avibactam). It was hard to evaluate how DCT would exhibit compared with the novel antibiotics.

Conclusions {#Sec17}
===========

Collectively, due to similar efficacy response and lower mortality, DCT could be used as an alternative therapeutic option in the treatment of MDR Gram-negative bacterial infections. More high-quality clinical trials were required to further address the efficacy, safety and risk of carbapenem resistance of DCT.
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:   Metallo-beta-lactamase

IMP

:   Imipenemase

VIM

:   Verona integron-encoded MBL

SPM

:   Sao Paulo MBL

GIM

:   German imipenemase

NDM

:   New Delhi MBL

OXA

:   Oxacillinase

MDR

:   Multidrug resistant

XDR

:   Extensively drug resistant

PDR

:   Pandrug resistant

MEM

:   Meropenem

ETP

:   Ertapenem

DOR

:   Doripenem

GEN

:   Gentamicin

CST

:   Colistin

TGC

:   Tigecycline

RIF

:   Rifampicin

AMG

:   Aminoglycosides

CAB

:   Carbapenem antibiotics

FLQ

:   Fluoroquinolones

CIP

:   Ciprofloxacin

AMK

:   Amikacin

FOF

:   Fosfomycin

LZD

:   Linezolid

PMB

:   Polymyxin B

DOX

:   Doxycycline

FCA

:   Fluconazole

AVC

:   Ceftazidime/avibactam

RCT

:   Randomized controlled trial

NOS

:   Newcastle-Ottawa Scale

MIC

:   Minimum inhibitory concentration

SD

:   Standard deviation

OR

:   Odds ratio

CI

:   Confidence interval

S

:   Sensitive

I

:   Intermediate

R

:   Resistant
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